MedTrace Logo

Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients

NCT07296627 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-12-22

No results posted yet for this study

Summary

To conduct a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in NDMM patients in China. Leveraging the extensive patient resources of China's large center for blood disorders, the investigator will recruit approximately 500 NDMM patients to establish an NDMM patient cohort. The investigator will collect data on disease characteristics, treatment patterns, and clinical outcomes through one year of clinical follow-up. Further long-term follow-up is needed to obtain survival status and causes of death, so as to provide essential evidence for optimizing and improving patients' prognosis in clinical individualized treatment.

Conditions

  • Newly Diagnosed Multiple Myeloma (NDMM)

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Prof. LU, MD · Peking University People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-16
Primary Completion
2027-07-15
Completion
2027-11-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07296627 on ClinicalTrials.gov